Protein C News and Research

RSS

Study suggests that previous COVID-19 infections do not affect pregnancy

A new study shows that it is exceedingly likely that past infection with SARS-CoV-2 has no significant effect on antibody or cytokine levels during pregnancy, labor or delivery.

6 Jan 2022

Researchers outline characteristics of Omicron variant immune escape and viral entry into host cells

A new study found that the Omicron variant contains a number of mutations that decrease neutralizing antibody activity and immune escape.

6 Jan 2022

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

New research shows evidence that the Omicron variant is less severe compared to the Delta variant.

6 Jan 2022

Emergence of a new SARS-CoV-2 variant from Southern France

A new study has described the emergence of another new SARS-CoV-2 variant from south-eastern France with Cameroonian origin.

6 Jan 2022

Small molecule identified as a SARS-CoV-2 inhibitor

A new study published in iScience reports the results of a screening strategy to identify small molecules that target viral entry to block infection with this virus.

6 Jan 2022

Host kinase identified as an inhibition target for SARS-CoV-2

In this experiment, the chemical probe SGC-CK2-1 inhibited virus replication at nanomolar concentration, showing a highly selective effect on the kinase.

6 Jan 2022

Serological antibody response to SARS-CoV-2 infection at a population level

The scientists in this study used pooled convalescent serum to examine the serologic response in a population at risk of infection.

6 Jan 2022

Study finds all three proteins required for SARS-CoV-2 infection present in human glossopharyngeal and vagal nerves

Researchers explored the presence of coronavirus receptors in the glossopharyngeal and vagal cranial nerves.

6 Jan 2022

Melatonin found to inhibit SARS-CoV-2 entry into mice brains

New research recently unveiled the utility of melatonin and melatonin-derived medicines in reducing brain entry of severe acute respiratory syndrome coronavirus 2 and subsequently preventing long-term neurological consequences of coronavirus disease 2019.

6 Jan 2022

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

PhoreMost Limited and Polaris Quantum Biotech (POLARISqb) today announced a collaboration to study oncology targets currently considered undruggable.

From PhoreMost 6 Jan 2022

SARS-CoV-2 appears to persist in organs throughout the body for months

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leads to asymptomatic or mild symptoms in most cases. However, in a significant minority, it causes moderate or severe disease, with lung damage and sometimes multi-organ dysfunction, the origin of which is currently a matter of intense debate.

6 Jan 2022

New engineered nanomaterials help capture chemotherapy drugs to avoid tissue damage

Standard chemotherapies may efficiently kill cancer cells, but they also pose significant risks to healthy cells, resulting in secondary illness and a diminished quality of life for patients. To prevent the previously unavoidable damage, researchers, led by Penn State, have developed a new class of nanomaterials engineered to capture chemotherapy drugs before they interact with healthy tissue.

6 Jan 2022

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

The LIVE-AIR phase 3 clinical trial is associated with early treatment of hyperinflammatory response with the humanized monoclonal antibody lenzilumab in COVID-19 patients with decreased oxygen saturation. The study results are posted to the medRxiv* preprint server.

6 Jan 2022

Protein C News and Research

Study suggests that previous COVID-19 infections do not affect pregnancy

Researchers outline characteristics of Omicron variant immune escape and viral entry into host cells

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

Emergence of a new SARS-CoV-2 variant from Southern France

Small molecule identified as a SARS-CoV-2 inhibitor

Host kinase identified as an inhibition target for SARS-CoV-2

Serological antibody response to SARS-CoV-2 infection at a population level

Study finds all three proteins required for SARS-CoV-2 infection present in human glossopharyngeal and vagal nerves

Melatonin found to inhibit SARS-CoV-2 entry into mice brains

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

SARS-CoV-2 appears to persist in organs throughout the body for months

New engineered nanomaterials help capture chemotherapy drugs to avoid tissue damage

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

New method to estimate how individual mutations affect transmission of SARS-CoV-2

After SARS-CoV-2 booster dose memory B cells adapt to Omicron

Change in glutathione reductase lowers inflammation in present-day humans

Scientists estimate transmission advantage of Omicron over Delta variant as +105%

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Monoclonal antibody treatment of COVID-19 reduces viral shedding

First-responder cells launching the repair after heart attack promote inflammation overdrive

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News